Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jazz Pharmaceuticals recently updated its Phase 2 clinical study on ZW25 (zanidatamab) combined with chemotherapy for HER2-expressing gastrointestinal cancers. The study aims to assess the safety and efficacy of this treatment in patients with gastroesophageal adenocarcinoma, biliary tract cancer, and colorectal cancer. This research is significant as it targets difficult-to-treat cancers with limited options.
The study tests ZW25 in combination with various chemotherapy regimens, including fluorouracil, cisplatin, leucovorin, oxaliplatin, capecitabine, and bevacizumab. These combinations aim to enhance anti-tumor activity and improve patient outcomes.
This interventional study is non-randomized with a parallel assignment and open-label design, focusing primarily on treatment. The study’s goal is to evaluate the therapeutic potential of ZW25 in combination with standard chemotherapy.
The study began on February 22, 2019, and was last updated on September 10, 2025. Although the primary completion date has passed, the study’s final results are still pending, indicating ongoing analysis and updates.
This update could positively influence Jazz Pharmaceuticals’ stock performance by showcasing potential advancements in cancer treatment. Investors might view this as a promising development, especially in the context of competitive oncology markets.
The study is ongoing, with further details available on the ClinicalTrials portal.